EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

An Ad26‐ MVA ‐ BN ‐based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infections

Selina Khan, Satish Boedhoe, Miranda Baert, Jan Serroyen, Thierry Verbinnen, Ariane Volkmann, Markus Kalla, Katrin Weidner, Mathieu Le Gars, Jerry Sadoff, Michal Sarnecki, Jort Vellinga und 4 weitere

Clinical & Translational Immunology · 2026-03 · 15 (3)

DOI: 10.1002/cti2.70089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 17.03.2026. Verfasst von Selina Khan und 15 weiteren Autor:innen. Beteiligte Einrichtung: Johnson & Johnson Leiden The Netherlands. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To develop a therapeutic human papillomavirus (HPV) vaccine capable of intercepting HPV‐related cervical disease to reduce the number of new cancer cases and associated deaths.

Methods

We previously reported that replication‐deficient adenovirus type 26 and 35‐based vectors (Ad26, Ad35) expressing a fusion protein of E2, E6 and E7 (E2SH) from HPV16 and HPV18 induced robust HPV‐specific T‐cell immunity capable of reducing HPV16+ tumors in mice. Here, we assessed immune responses induced by Ad26 and Modified Vaccinia Virus Ankara—strain Bavarian Nordic (MVA‐BN) viral vectors expressing E2SH in heterologous vaccination regimens in mice, macaques and a limited number of persistently HPV‐infected women ( N = 5).

Results

The magnitude and breadth of cellular immune responses were higher in mice that received Ad26.HPV16/18‐MVA‐BN.HPV16/18 than in those that received Ad26.HPV16/18‐Ad35.HPV16/18, all expressing the fusion protein E2SH of HPV16 and HPV18. Sustained and broad antigen‐specific systemic T‐cell responses against HPV16 and HPV18 proteins were induced in macaques. In the Phase 1/2a trial, a 2‐dose heterologous immunisation with Ad26.HPV16 or Ad26.HPV18 in Week 0 and MVA‐BN.HPV16/18 in Week 8 induced long‐lived antigen‐specific cytokine‐producing T cells. After Week 8, HPV16/18 infection was no longer detected in 5/5 active vaccines and 1/4 placebo recipients during the study period of approximately 1 year. The small number of vaccinated participants did not allow concluding on the relationship between immune responses and viral clearance.

Conclusion

These data show the ability of Ad26.HPV16/18‐MVA‐BN.HPV16/18 heterologous regimens to elicit HPV‐specific T‐cell responses and warrant further clinical studies to evaluate vaccine efficacy.

Schlagwörter

Stichwörter der Autor:innen

adenoviral vectorhuman papillomavirusmodified vaccinia Ankaratherapeutic vaccine

Autor:innen und Institutionen

  • Johnson & Johnson Leiden The Netherlands.
  • Present address: Oncode Accelerator Foundation Utrecht The Netherlands.
  • Johnson & Johnson Beerse Belgium.
  • Bavarian Nordic GmbH Martinsried Germany.
  • Johnson & Johnson Janssen Vaccines Bern Switzerland.

Zitieren

APA

Khan, S., Boedhoe, S., Baert, M., Serroyen, J., Verbinnen, T., Volkmann, A., Kalla, M., Weidner, K., Gars, M. L., Sadoff, J., Sarnecki, M., Vellinga, J., Custers, J., Scheper, G., Schuitemaker, H., & Zahn, R. (2026). An Ad26‐ MVA ‐ BN ‐based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infections. Clinical & Translational Immunology, 15(3). https://doi.org/10.1002/cti2.70089

Vancouver

Khan S, Boedhoe S, Baert M, Serroyen J, Verbinnen T, Volkmann A, et al. An Ad26‐ MVA ‐ BN ‐based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infections. Clinical & Translational Immunology. 2026;15(3). doi:10.1002/cti2.70089

BibTeX
@article{Khan2026,
  author = {Khan, Selina and Boedhoe, Satish and Baert, Miranda and Serroyen, Jan and Verbinnen, Thierry and Volkmann, Ariane and Kalla, Markus and Weidner, Katrin and Gars, Mathieu Le and Sadoff, Jerry and Sarnecki, Michal and Vellinga, Jort and Custers, Jerome and Scheper, Gert and Schuitemaker, Hanneke and Zahn, Roland},
  title = {An Ad26‐ MVA ‐ BN ‐based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infections},
  journal = {Clinical & Translational Immunology},
  year = {2026},
  volume = {15},
  number = {3},
  doi = {10.1002/cti2.70089}
}
Kostenlos starten →